A US appeals court upheld a decision siding with Parse Biosciences in a patent dispute against 10x Genomics. The US Court of Appeals for the Federal Circuit affirmed invalidation of three Parse-challenged patents related to single-cell nucleic acid analysis. The litigation centered on 10x’s Evercode Whole Transcriptome assay and three patent numbers, which Parse argued were unpatentable as obvious. The Patent Trial and Appeal Board initially ruled that the claims lacked sufficient inventive step, and 10x appealed. According to the court outcome, Parse’s position prevailed at the Federal Circuit level. The ruling was described as distinct from a separate Delaware district court decision that previously invalidated another patent tied to Scale Biosciences, which was later acquired into the 10x ecosystem. Parse, now under Qiagen after a late-2025 acquisition, said it welcomed the Federal Circuit affirmance. For single-cell transcriptomics competitors, the decision reinforces how key method patents can be narrowed or removed through post-grant challenges.